Form 13-F position report

PTC THERAPEUTICS INC

Reported by JANUS HENDERSON GROUP PLC

PTCT CUSIP 69366J200 Manager CIK 0001274173

Reported 4,851,332 shares, up 1,077,776 (28.6%) from the prior quarter.

Reported value 59.1%; share count 28.6% vs. the prior quarter.

Added
% of reported 13F value 0.17% This manager · Q4 2025
Shares 4,851,332 Quarter-end amount reported
Reported value $368,586,978 Fair value at quarter end
Consecutive quarters held 28 Through Q4 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-06-30 148107000
2021-09-30 133035000
2021-12-31 155397000
2022-03-31 100070000
2022-06-30 85563000
2022-09-30 103175000
2022-12-31 77374244
2023-03-31 154839364
2023-06-30 146296747
2023-09-30 68847799
2023-12-31 72004402
2024-03-31 106744465
2024-06-30 91147762
2024-09-30 69390965
2024-12-31 105015067
2025-03-31 158151955
2025-06-30 155010652
2025-09-30 231685032
2025-12-31 368586978
2026-03-31 489997100

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for PTC THERAPEUTICS INC held by JANUS HENDERSON GROUP PLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Added 7,193,433 +2,342,101 (48.3%) 0.23% $489,997,100 2026-05-15
Q4 2025 Added 4,851,332 +1,077,776 (28.6%) 0.17% $368,586,978 2026-02-17
Q3 2025 Added 3,773,556 +598,541 (18.9%) 0.11% $231,685,032 2025-11-14
Q2 2025 Added 3,175,015 +258,286 (8.9%) 0.08% $155,010,652 2025-08-14
Q1 2025 Added 2,916,729 +590,814 (25.4%) 0.09% $158,151,955 2025-05-15
Q4 2024 Added 2,325,915 +455,698 (24.4%) 0.05% $105,015,067 2025-02-14
Q3 2024 Reduced 1,870,217 -1,111,342 (-37.3%) 0.04% $69,390,965 2024-11-14
Q2 2024 Reduced 2,981,559 -688,257 (-18.8%) 0.05% $91,147,762 2024-08-14
Q1 2024 Added 3,669,816 +1,057,223 (40.5%) 0.06% $106,744,465 2024-05-15
Q4 2023 Reduced 2,612,593 -459,727 (-15.0%) 0.04% $72,004,402 2024-02-14
Q3 2023 Reduced 3,072,320 -524,430 (-14.6%) 0.05% $68,847,799 2023-11-14
Q2 2023 Added 3,596,750 +400,446 (12.5%) 0.09% $146,296,747 2023-08-14
Q1 2023 Added 3,196,304 +1,169,162 (57.7%) 0.1% $154,839,364 2023-05-15
Q4 2022 Reduced 2,027,142 -28,009 (-1.4%) 0.06% $77,374,244 2023-02-14
Q3 2022 Reduced 2,055,151 -80,525 (-3.8%) 0.09% $103,175,000 2022-11-14
Q2 2022 Reduced 2,135,676 -546,298 (-20.4%) 0.06% $85,563,000 2022-08-15
Q1 2022 Reduced 2,681,974 -1,219,423 (-31.3%) 0.05% $100,070,000 2022-05-16
Q4 2021 Added 3,901,397 +326,210 (9.1%) 0.06% $155,397,000 2022-02-14
Q3 2021 Added 3,575,187 +71,273 (2.0%) 0.06% $133,035,000 2021-11-16
Q2 2021 Added 3,503,914 +434,774 (14.2%) 0.06% $148,107,000 2021-08-16
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

391 managers reported PTC THERAPEUTICS INC for Q4 2025.

Managers reporting PTC THERAPEUTICS INC in Q4 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 12,779,065 +5,648,258 0.02% $970,697,777 6 qtrs
VANGUARD GROUP INC Added 8,803,203 +514,204 < 0.01% $668,691,300 50 qtrs
RTW INVESTMENTS LP Unchanged 7,746,415 0 5.89% $588,417,683 37 qtrs
JANUS HENDERSON GROUP PLC This report Added 4,851,332 +1,077,776 0.17% $368,586,978 28 qtrs
STATE STREET CORPORATION Added 4,206,126 +1,071,343 0.01% $319,497,331 50 qtrs
TORONTO DOMINION BANK Added 4,138,215 +891,690 0.46% $314,338,811 5 qtrs
WELLINGTON MANAGEMENT GROUP LLP Reduced 3,867,380 -1,051,239 0.05% $293,766,184 50 qtrs
ARMISTICE CAPITAL LLC Reduced 2,801,869 -475,403 2.53% $212,829,969 29 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,016,062 +65,184 < 0.01% $153,164,342 50 qtrs
D E Shaw & Co Inc Reduced 1,744,991 -429,617 0.07% $132,549,516 42 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2025
Filed
February 17, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
4,655,604
None
195,728

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.